OXiGENE Reports Commencement of Phase 2 Study of Fosbretabulin By: Benzinga via Benzinga September 17, 2014 at 16:02 PM EDT OXiGENE, Inc. (Nasdaq: OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that the first patient ... Read More >>